Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird's fall from the one of the buzziest biotech ...
While commercial revenue has yet to materialize in bluebird bio’s earnings report, the company is flying high on the launches of its two new gene therapies Zynteglo and Skysona. After last year’s back ...
Southern Living on MSN
Should You Put Up A Bird Feeder In Winter? Here's What The Experts Say
After any snowfall, wild sources of food may also be hidden. "Putting up a bird feeder is important in winter if natural food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback